Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT04457284
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Colorectal Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Temozolomide (TMZ) — DRUG
    TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1 TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +
  • Cisplatin — DRUG
    Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +
  • Nivolumab — DRUG
    Nivolumab 480 mg Q4W IV infusion Cycle 1 +

Study Details

This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The researchers will also look at how safe the study drug combination is in participants.

Key Dates

Start date
Nov 18, 2020
Status verified
Mar 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: temozolomide, cisplatin and nivolumab
    Subjects will receive oral TMZ at 150-200 mg/m2 day 1 to 5 every 4 weeks, cisplatin via IV infusion at 40 mg/m2 every two weeks (Q2W), and nivolumab via IV infusion at 480 mg every four weeks (Q4W).

Primary Outcome Measure

Response [ Time Frame: 1 year ]

Locations (7)

Find similar trials in Basking Ridge, NJ

Related Studies